Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 5/20 | 0.37 |
| ▸ | FPR2 | P25090 | 5/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30508386 | 0.85 | RORC (0.47) | RORCFPR3FPR2JAK2JAK1 | |
| SCHEMBL3701782 | 0.83 | RORC (0.48) | RORCFPR3FPR2JAK2JAK1 | |
| SCHEMBL23262819 | 0.81 | ACACB (0.39) | ALDH1A1CYP11B2 | |
| SCHEMBL351459 | 0.79 | TSHR (0.47) | RORCJAK2JAK1CCR5CYP11B2 | |
| SCHEMBL28601266 | 0.77 | MAPT (0.43) | MAPK1SMN1; SMN2FPR2ALDH1A1KMT2A | |
| SCHEMBL3701066 | 0.77 | RORC (0.50) | RORCKMT2A | |
| SCHEMBL1427288 | 0.77 | RORC (0.49) | RORCSMN1; SMN2FPR3FPR2JAK2 | |
| SCHEMBL16936274 | 0.76 | RORC (0.53) | RORCFPR3FPR2JAK2JAK1 | |
| SCHEMBL16936273 | 0.76 | RORC (0.53) | RORCFPR3FPR2JAK2JAK1 | |
| SCHEMBL18226512 | 0.76 | RORC (0.53) | RORCFPR3FPR2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901152-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8242139-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2452937-A1 | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | Abbott Laboratories (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | RORC 4088/4885MAPK1 1316/4885SMN1; SMN2 4304/4885 |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | RORC 4088/4885MAPK1 1316/4885SMN1; SMN2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.